



Title: Leucine supplementation increases muscle strength and volume, reduces inflammation 
and affects wellbeing in adults and adolescents with cerebral palsy. 
 
Author names: 
Nicola Theis1, Meghan A. Brown1, Paula Wood2, Mark Waldron3,4*  
Affiliations: 
1School of Sport and Exercise, University of Gloucestershire, Gloucestershire, UK 
2Treloar’s School and College, Treloar’s Trust, Alton, Hampshire, UK 
3College of Engineering, Swansea University, Swansea, UK 
4School of Science and Technology, University of New England, NSW, Australia. 
Sources of support: None. 
Conflict of interest and funding disclosure: 
Theis: No conflicts of interest 
Brown: No conflicts of interest 
Wood: No conflicts of interest 
Waldron: No conflicts of interest 
*Contact Details for the Corresponding Author: 
Dr Mark Waldron, College of Engineering, Swansea University, Bay Campus, Swansea, 
SA20RZ (mark.waldron@swansea.ac.uk). 
Word count: 3264 
Tables: 3 
Supplementary: 1
  2 
Running title: Leucine supplementation in cerebral palsy 1 
 2 
Abbreviations:  3 
Brach-chain amino acid (BCAA) 4 
Cerebral palsy (CP) 5 
Coefficient of variation (CV) 6 
Confidence interval (CI) 7 
C-reactive protein (CRP) 8 
Gross motor function classification system (GMFCS) 9 
Trial registration: 10 
NCT03668548 registered at www.clinicaltrials.gov 11 
 12 
  13 
  2 
Abstract 14 
Background: Spastic cerebral palsy (CP) is characterised by muscle weakness owing, in part, 15 
to a blunted muscle protein synthetic response. This might be normalized by long-term leucine 16 
supplementation.  17 
Objectives: The study assessed the effects of 10-week leucine supplementation in adolescents 18 
and adults with CP. 19 
Methods: The study was a single-centre randomised controlled trial. Twenty-four participants 20 
were randomised to a control group (n = 12) or a leucine group (n = 12). L-Leucine (192 mg/kg 21 
body mass) was dissolved in water and administered daily for 10 weeks. Primary outcome 22 
measures; elbow flexor muscle strength and muscle volume (measured by 3D ultrasound 23 
technique) and inflammation (C-reactive protein concentration) were assessed before and after 24 
10 weeks, alongside secondary outcomes; body composition (measured by CP-specific 25 
skinfold assessment), metabolic rate (measured by indirect calorimetry) and wellbeing (self-26 
reported daily questionnaire). Data were compared with a series of two-way mixed ANOVA’s. 27 
Results: Twenty-one participants completed the intervention (mean ± SD, control group: n = 28 
11, age: 18.3 ± 2.8 y, body mass: 48.8 ± 11.9 kg, 45% male; leucine group: n = 10, age: 18.6 ± 29 
1.7 y, body mass: 58.3 ± 20.2 kg, 70% male). After 10 weeks, there was a 25.4% increase in 30 
strength (p = 0.019) and a 3.6% increase in muscle volume (p = 0.001) in the leucine group 31 
with no changes in the control group. This was accompanied by a 59.1% reduction in CRP (p 32 
= 0.045) and improved perceptions of wellbeing (p = 0.006). No changes in metabolism or 33 
body composition were observed in either group (p > 0.05). 34 
Conclusions: Improvements in muscle strength and volume with leucine supplementation 35 
might provide important functional changes for adults and adolescents with CP and could be 36 
partly explained by reduced inflammation. The improved wellbeing highlights its capacity to 37 
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Cerebral palsy (CP) is caused by damage to the developing brain and descending pathways, 43 
leading to altered patterns of growth and development (1). Those with CP may encounter early 44 
symptoms of paresis and spasticity, leading to increased muscle atrophy (2) and abnormal 45 
growth of contractile and non‐contractile tissue (3). This causes significant weakness of the 46 
muscle and compromises daily function (4). As such, interventions aimed at increasing muscle 47 
mass or preventing muscle atrophy for those with CP must be established. 48 
 49 
For those with CP, several factors may contribute to reduced levels of protein synthesis and 50 
therefore, muscle atrophy or diminished growth capacity. For example, sub-optimal nutritional 51 
status (5) and oropharyngeal dysfunction (6) can hinder feeding. Furthermore, chronic low-52 
grade inflammation has been linked to sustained neurological injury (7) and the observed 53 
reductions in physical activity and chronic inflammation have been shown to block protein 54 
synthesis pathways (8), thus promoting a negative net protein balance (9). Ingestion of the 55 
branched-chain amino acid (BCAA) leucine has been shown to augment anti-inflammatory 56 
networks (10), stimulate protein synthesis pathways, and potentially provide antiproteolytic 57 
effects, resulting in a positive protein balance and potential net muscle mass gain (11-12). The 58 
provision of high-quality amino acid solutions via beverages might circumvent the feeding 59 
issues that arise from oral motor dysfunction among those with CP, as well as assisting with 60 
energy and protein balance.  61 
 62 
There are various other benefits to leucine supplementation among those with CP. For example, 63 
increases in resting metabolism and changes in substrate utilisation might help to offset the 64 
health risks of sedentary behaviour and muscle atrophy reported in this population (13). 65 




promote lean body mass (15). Furthermore, the health and wellbeing of those with CP can be 67 
challenged by various social, environmental and personal constraints (16), which can lead to 68 
emotional problems and low life satisfaction (17). Changes in plasma BCAA availability can 69 
have neurochemical and functional consequences in the brain and, while their effects on 70 
cerebral function are controversial (18), inadequate diet or under-nourishment is likely to 71 
disrupt mood state (19) which could be offset by oral BCAA administration in addition to a 72 
calorie controlled-diet. However, there has been no investigation of the effects of leucine 73 
supplementation on wellbeing in CP. Therefore, the purpose of this study was to assess the 74 
effects of 10-weeks leucine supplementation on muscle growth, metabolism, body 75 
composition, inflammation and wellbeing in adolescents and young adults with CP.   76 
 77 
Methods 78 
Study design and participants 79 
The study was a single-centre randomised controlled trial comparing 10 weeks of leucine 80 
supplementation with a control. Adolescents and young adults with CP were recruited from a 81 
special educational needs school and college. Inclusion criteria were: 1) a diagnosis of spastic 82 
cerebral palsy 2) Gross Motor Function Classification System (GMFCS) II-V 3) aged 12-25 83 
years. Exclusion criteria included: 1) orthopaedic surgery of the upper-limbs in the past 12 84 
months 2) botulinum toxin type A injections in the past 6 months 3) serial casting in the past 6 85 
months 4) insufficient cognitive understanding to comply with procedures. Parental/guardian 86 
consent was obtained from participants under 18 years. Those over 18 years gave their own 87 
written or verbal consent in the presence of a carer. Ethical approval was granted by an 88 





The randomization schedule with a 1:1 allocation ratio was generated by an individual 91 
independent to the study prior to the start of recruitment. The same individual placed allocation 92 
of participants in sequentially numbered opaque sealed envelopes. The trial manager revealed 93 





Participants completed testing at baseline and after 10 weeks at a similar time of day. All 99 
participants (with assistance from parents/guardians or carers where required) were asked to 100 
complete a daily food and fluid diary (including feeds and supplements aside from the 101 
intervention drink) and a daily wellbeing questionnaire throughout the trial period. Three days 102 
of food diaries within the first two weeks of the study were analysed using dietary analysis 103 
software (Nutritics Ltd, Swords, Ireland) to determine mean daily energy and macronutrient 104 
intake. Based on published upper tolerable limits of children (20), the intervention group were 105 
supplemented daily with 192 mg/kg body mass of L-leucine, up to 15 g (12.4 ± 2.2 g) (Bulk 106 
Powders, Sports Supplements Ltd., Essex, UK) dissolved with 300 ml of water and 107 
approximately 50 ml of fruit concentrate (Robinsons Orange Squash, Britvic Soft Drinks, 108 
Herefordshire, UK), to mask the taste of leucine, while the control group were provided with 109 
300 ml of water and 50 ml of fruit concentrate drink. The drinks were prepared by people 110 
independent to the study and consumed by participants throughout the day for 10 weeks. In 111 
this time, all participants were asked to maintain their typical eating and activity routines. 112 
 113 




Muscle strength. Elbow flexor strength was assessed using hand-held dynamometry (FDIX, 115 
Wagner Instruments, Greenwich, CT). The dynamometer was fixed to a rigid custom-made 116 
device, which allowed participants to perform isometric elbow flexion contractions at 117 
approximately 90°. The dynamometer was placed perpendicular to the arm to be tested, and 118 
mid-way between the elbow and wrist, on the least affected arm. With all participants in a 119 
seated position, resistance was applied by the examiner to avoid movement of the limb being 120 
tested (Coefficient of variation (CV%) = 13.1). A rest period of 30 s was given between three 121 
consecutive trials. If trials differed by >10% an additional trial was performed. The trial with 122 
the highest recorded force was used for further analysis.  123 
 124 
Muscle volume. Muscle volume of the elbow flexors from the least affected arm were measured 125 
using two-dimensional B-mode ultrasound images combined with 3D motion data (Stradwin 126 
v5.1 software, Mechanical Engineering, Cambridge University, Cambridge, UK) using 127 
previously established methods (21). Bicep brachii and brachialis muscle boundaries were 128 
identified and digitised, and volume reconstructions were computed. Muscle volumes of biceps 129 
brachii and brachialis were summed to give an overall elbow flexor muscle volume. Every third 130 
frame of the muscle sweep was segmented and reconstructed into a rendered 3D muscle (CV% 131 
= 1.2) along with the values of the reconstructed muscle volume.  132 
 133 
C-reactive protein. The index fingertip or in the case of severe spasticity, the earlobe, of the 134 
participant was cleaned using a sterile alcohol swab and allowed to air dry. Capillary blood 135 
was drawn and a sample of whole blood (300 μL) was collected into a capillary tube and 136 
centrifuged at 3000 r/min for 5 min. The resultant plasma was removed and stored at -20°C. 137 
C-reactive protein was quantified using a commercially available, latex particle-enhanced 138 




spectrophotometrically using an automated system (Cobas 8000 c702 analyser, Roche 140 
Diagnostics, Burgess Hill, UK). The analytical characteristics were: limit of detection 0.3 141 
mg/L; limit of quantitation 0.6 mg/L; mean laboratory inter-assay CV% during the study was 142 
3.5% at a level of 26.5 mg/L and 10.6% at a level of 133.2 mg/L.  143 
 144 
Wellbeing. The daily wellbeing questionnaire asked participants to rate their fatigue, sleep 145 
quality, general muscle soreness, stress levels and mood on a five-point scale (scores of 1 to 5) 146 
(22). Wellbeing was then determined by summing the five scores. The median rating for each 147 
variable across week 1 and week 10 were compared between groups.  148 
 149 
Secondary outcome measures 150 
Fat and carbohydrate oxidation and resting energy expenditure. Resting energy expenditure 151 
was calculated via indirect calorimetry collected using a portable metabolic system (K4 b2, 152 
Cosmed, Italy), which was calibrated before every use with one reference gas mixture (95% 153 
O2, 5% CO2). Indirect calorimetry was performed whilst participants were in a seated or supine 154 
position for approximately 10 min. The same position and rest period was maintained for pre 155 
and post measurements. All measures were taken in the morning <60 min after wakening and 156 
with each participant fasted for a minimum of 8 h. Mean data from the final 2 min of gas 157 
collection were utilised for analysis. Steady state was confirmed by inspection of the oxygen 158 
uptake values and fat and carbohydrate oxidation and resting energy expenditure were 159 
calculated based on previous equations (23). 160 
 161 
Body composition. Percentage body fat was estimated based on CP-specific prediction 162 
equations (24), which incorporate GMFCS level, maturational status and two-site skinfold 163 




from the least affected side was taken in all participants using standardized techniques 165 
(Harpenden calipers, CMS Weighing Equipment Ltd, London, UK). Participants GMFCS level 166 
was assessed by a Physiotherapist. For use in the equations, GMFCS was categorized into two 167 
groups: ‘more severe’ (GMFCS levels III, IV, V) and ‘less severe’ (GMFCS levels I, II)24. 168 
Maturational status was assessed by means of secondary sex characteristics (breasts in females; 169 
pubic hair in males) (25). Observations were self-reported in those over 18 years or performed 170 
by parents/guardians or carers in those under 18 years. A Tanner stage of 1 or 2 was defined as 171 
prepubescent, Tanner stage 3 was defined as pubescent, and Tanner stage 4 or 5 was defined 172 
as post‐pubescent (25). Estimated body fat percentage was then calculated based on the 173 
prediction equations (24) and corrections for children with CP (26). This was subtracted from 174 
body mass at each time point to give lean body mass.  175 
 176 
Data analysis 177 
A sample of twenty-four participants with was required, based on an effect size of 0.30, 178 
statistical power of 0.80 and inclusive of a 30% dropout. Primary analyses were “per-protocol” 179 
from participants who completed >70% of supplementation and took part in both pre and post 180 
testing.  Independent samples t-tests were conducted to assess any baseline differences in the 181 
dependent variables (muscle strength, muscle volume, C-reactive protein, fat and carbohydrate 182 
oxidation, resting energy expenditure, body fat percentage, sum of skinfolds, and perceptions 183 
of wellbeing). In addition, independent t-tests were also performed to assess baseline 184 
differences in mean daily total energy intake and macronutrient contributions (g, % of total 185 
energy intake) between groups.  186 
 187 
To address the main purpose of the study, a series of two-way within and between analysis of 188 




(control and leucine) on the dependent variables (muscle strength, muscle volume, C-reactive 190 
protein, fat and carbohydrate oxidation, resting energy expenditure, body fat percentage, sum 191 
of skinfolds, and perceptions of wellbeing). In case of a significant interaction, post hoc tests 192 
were performed between groups (independent t-tests) and between time points (paired t-tests). 193 
A bonferroni correction was performed to adjust for multiple comparisons. Data were presented 194 
as mean ± SD, mean difference with 95% confidence intervals and Cohen’s D effect size. 195 
 196 
Results 197 
Initial recruitment to the study began in August 2018 and post-testing was completed in 198 
October 2018. Of the initial 24 participants recruited, one participant withdrew outlining 199 
personal reasons, one withdrew due to inability to take the supplement and one was not 200 
included in the final analysis because of non-compliance with the protocol (leucine: n = 10; 201 
control: n = 11) (Supplementary Figure 1). This resulted in 88% compliance to the study. Final 202 
group characteristics are presented in Table 1.  203 
 204 
Dietary analysis 205 
Nineteen participants (n = 8 leucine; n = 11 control) completed three days of food diaries within 206 
the first two weeks of the study (n = 2 diaries were incomplete). Independent samples t-tests 207 
revealed there were no differences in the mean daily total energy intake (kcal, MJ) and 208 
macronutrient contributions (g, % of total energy intake) of participants’ typical diets between 209 
groups (Table 2).  210 
 211 
Muscle strength, volume and CRP 212 
One participant was not included in the analysis for muscle strength and muscle volume as they 213 




muscle volume. Blood samples for CRP analysis were not taken from two participants in the 215 
leucine group and three participants in the control group due to non-compliance. Independent 216 
t-tests revealed there were no baseline differences between groups for muscle strength (p = 217 
0.084), muscle volume (p = 0.452) or CRP (p = 0.594). Results of the ANOVA demonstrated 218 
significant interaction effects for muscle strength (p = 0.019) muscle volume (p < 0.001) and 219 
CRP (p = 0.045). Post hoc tests demonstrated that after 10 weeks of leucine supplementation, 220 
muscle strength, muscle volume and CRP were significantly higher in the leucine group (p < 221 
0.001) compared to the control group (p > 0.05) (Table 3). 222 
Substrate oxidation, resting energy expenditure and body composition 223 
The results of independent t-tests revealed no baseline differences in fat oxidation (p = 0.506), 224 
carbohydrate oxidation (p = 0.095), resting energy expenditure (p = 0.319), body fat (p = 0.958) 225 
or sum of skinfolds (p = 0.098). Results of the ANOVA’s revealed no changes between groups 226 
or over time for fat oxidation (p = 0.662) carbohydrate oxidation (p = 0.307) or resting energy 227 
expenditure (p = 0.218) (respiratory exchange ratio: Pre = 0.88 ± 0.07; Post = 0.89 ± 0.07). 228 
Skinfold measures were not possible on one participant in the leucine group and two in the 229 
control group. For all other participants, there were no changes in body fat (p = 0.451) or the 230 
sum of skinfolds (p = 0.174) between groups after 10 weeks of leucine supplementation (Table 231 
3).  232 
Wellbeing 233 
Independent t-tests revealed no baseline differences between groups for wellbeing variables (p 234 
> 0.05). The results of the ANOVA demonstrated significant interaction effects for muscle 235 
soreness (p = 0.010), stress levels (p = 0.011), mood (p = 0.048) and general wellbeing (p = 236 
0.035). Post hoc tests demonstrated that after 10 weeks of leucine supplementation, muscle 237 
soreness and stress levels were significantly lower in the leucine group (p < 0.01), with no 238 




and general wellbeing were significantly greater in the leucine group after 10 weeks of 240 
supplementation (p < 0.05), with no changes in the control group (p > 0.05) (Table 3). There 241 
were no changes in ratings of fatigue (p = 0.770) or sleep quality (p = 0.924), between groups 242 
after 10 weeks of leucine supplementation (Table 3). 243 
 244 
Discussion 245 
This is the first study to report that 10 weeks of leucine ingestion in young adults and 246 
adolescents with moderate to severe CP significantly reduces inflammation, with concomitant 247 
improvements in muscle strength, muscle volume and perceptions of muscle soreness, stress, 248 
mood and general wellbeing.  249 
 250 
The increases in both muscle volume and strength conferred by leucine supplementation could 251 
provide important functional changes to individuals with CP. There are few studies monitoring 252 
changes in muscle volume following dietary amino acid supplementation. One study reported 253 
increases in muscle mass following a 13-week, high-protein, leucine-enriched (6 g/day) diet 254 
among elderly sarcopenic subjects, without structured exercise interventions, lending support 255 
to the reported anabolic actions of leucine in skeletal muscle (27). To date, there has been no 256 
study to demonstrate anabolic resistance in those with CP, yet the sedentary lifestyles and 257 
prevalence of malnutrition makes this a plausible outcome (1). Physical activity is known to 258 
augment the anabolic actions of leucine-rich diets (28), thus overcoming anabolic resistive 259 
thresholds, but inducing a traditional physical activity stimulus is practically challenging 260 
among many of those with moderate to severe CP. However, the finding that strength and 261 
muscle size were increased after 10 weeks of leucine ingestion infers an anabolic effect. Not 262 
all studies have reported changes in muscle mass after leucine supplementation (29) and there 263 




(30).  However, 3 g of isolated leucine without additional amino acids, can maximally stimulate 265 
protein synthesis (30). Here, protein metabolism was not measured but we can speculate that 266 
the increase in muscle volume and strength was probably the result of leucine-mediated 267 
increases in the rates of muscle protein synthesis, and/or reductions in muscle protein 268 
breakdown. 269 
A descriptive evaluation of individual responses to leucine supplementation in our study 270 
suggests that those who demonstrated the greatest responses had either; greater levels of gross 271 
motor function, and were more physically active (i.e. voluntary energy expenditure), or; were 272 
those with poor motor function but very high levels of spasticity (i.e. involuntary energy 273 
expenditure). However, whilst each of these energy-demanding processes is capable of 274 
augmenting anabolic singling and subsequent muscle protein synthesis in combination with the 275 
leucine supplementation (11,28,31), there is currently no valid or unified approach to 276 
monitoring daily energy expenditure and/or physical activity levels among those with severe 277 
spastic cerebral palsy during free living. For example, involuntary muscular contraction, 278 
induced by spasticity, was present in the majority of participants in this study and has been 279 
considered a source of excessive energy expenditure (28), which may augment the anabolic 280 
action of leucine, yet this cannot be objectively quantified at present. Therefore, whilst it was 281 
not possible to quantify the extent and magnitude of spasticity over a 10-week period, our 282 
results suggest the leucine response may be modulated, to some extent, by spastic episodes 283 
even in the absence of a traditional physical activity stimulus. Based on this reasoning, there is 284 
grounds for further research to develop the current understanding of energy-demanding 285 
activities (voluntary or otherwise) among those with CP and their synergistic effects with 286 
leucine supplementation for promoting muscle growth. Despite reporting changes in muscle 287 
volume of one muscle group, we did not find changes in resting metabolic rate, substrate 288 




composition equations utilised were not sufficiently accurate in the current group, leading to 290 
erroneous values and a failure to detect changes in body composition. More work is necessary 291 
to confirm these findings, as well as determine the direct effects of leucine supplementation on 292 
muscle protein synthesis in CP groups.  293 
 294 
We are the first to provide evidence of the potential systemic anti-inflammatory role of leucine 295 
supplementation among those with CP, highlighted by a significant reduction in CRP 296 
concentration across the 10-week period in the leucine group. The administration of leucine-297 
rich amino acids is known to stimulate anti-inflammatory networks (10). Chronic inflammation 298 
has been reported among those with CP (1, 7) and increases in intermuscular adipose tissue is 299 
a probable contributor, based on our body fat estimations and the reported sedentary behaviours 300 
of non-ambulant individuals. The changes in CRP coincided with a reduction in perceived 301 
muscle soreness, which can be related to reductions in systemic inflammation. Our findings 302 
are consistent with others, whereby leucine-rich protein diets have been shown to reduce CRP 303 
in elderly subjects (15), as well as recent meta-analytic findings demonstrating the accentuated 304 
anti-inflammatory effects of whey protein diets on CRP among those with chronic low-grade 305 
inflammation (32). Therefore, we provide the first evidence that leucine could have an anti-306 
inflammatory effect on those with CP and that this appears alongside increased muscle 307 
function, muscle mass and reduced soreness.    308 
 309 
The observed improvements in the composite wellbeing score of the leucine group were 310 
attributable to changes in muscle soreness, stress and mood across the 10-week period. The 311 
energy intake was not different between the two groups, suggesting that the addition of leucine 312 
to the diet improved wellbeing. Those with CP face daily emotional challenges and often live 313 




mood (17). Therefore, there is feasible capacity to improve the general daily wellbeing of those 315 
with CP, as demonstrated herein. There are a variety of mechanisms that link symptoms of 316 
depression, including mood states and perceived stress, to dysregulated serotonin (5-HT) 317 
within the brain. BCAAs (such as leucine) provide alternative precursors of 5-HT and can 318 
offset the depletion of others (tryptophan, TRP) (18). Indeed, supplements containing TRP and 319 
other amino acids have been shown to positively affect mood and depressive symptoms (33). 320 
The mechanistic basis of this association could be explained by the reduced blood-to-brain 321 
transfer of kynurenine reported in the mouse model following leucine treatment (34) but this 322 
requires further research in humans. However, given the adherence of the participants to the 323 
dietary regime, it is possible that this was not the underlying reason, since competitive 324 
inhibition of TRP uptake at the blood brain barrier can occur (35). Whilst the changes noted in 325 
our study are unlikely to provide a permanent solution to wellbeing problems in those with CP, 326 
it appears that leucine supplementation at least transiently alleviated low mood or stressed 327 
states.  328 
In conclusion, ten weeks of leucine ingestion (192 mg/kg, ~9 - 15 g) provided a variety of 329 
benefits to young adults and adolescents with moderate to severe CP. The changes in muscle 330 
strength and muscle volume might provide important functional changes and could be partly 331 
explained by the reduced systemic inflammation. The improved wellbeing of the leucine-fed 332 
CP group also highlights its alternative roles and capacity to improve the quality of daily living. 333 
There is some evidence that physical activity and/or repeated involuntary muscle activity may 334 
provide superior improvements in muscle strength, muscle volume and CRP after leucine 335 
supplementation in this population, but this warrants further investigation. 336 
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Table 1. Participant characteristics of adults and adolescents with CP in the leucine (n = 10) 
or control groups (n = 11)1  
 




18.6 ± 1.7 
 
18.3 ± 2.8 
Sex 7 male, 3 female 5 male, 6 female 












































Table 2. Daily energy and macronutrient intakes of typical diet of adults and adolescents with 
CP in the leucine (n = 8) or control groups (n = 11)1  
Intake Leucine Control P value 
Energy Intake, kcal 1523 ± 429 1881 ± 648 0.193 
MJ 6.4 ± 1.8 7.9 ± 2.7 0.193 
Carbohydrate, g 160 ± 46 211 ± 70 0.092 
% energy 43 ± 11 45 ± 4 0.486 
Protein, g  62 ± 22 74 ± 31 0.371 
% energy 16 ± 4 16 ± 3 0.680 
Fat, g  70 ± 31 79 ± 33 0.551 
% energy 41 ± 9 37 ± 7 0.335 
1As determined using dietary analysis software (Nutritics Ltd, Swords, Ireland) from 3-day 





Table 3. Dependent variables before and after 10 weeks of leucine supplementation in adults and 
adolescents with CP randomized to a leucine group (n = 10) or control group (n = 11) 
 Leucine group  Control group  




Mean difference (95% 
CI), Cohen’s D 
0 weeks  10 weeks  Mean difference (95% 
CI), Cohen’s D 
P-interaction 
(group × time) 
Muscle strength, N 133.2 ± 60.9 167.0 ± 48.6*† 33.8 (79.8 to -12.2), 
0.60 
78.0 ± 75.7 77.0 ± 53.4 1.0 (58.4 to -56.4), -
0.01 
0.019 
Muscle volume, cm3 
 
162.3 ± 22.4 168.1 ± 24.2*† 5.8 (25.3 to -13.7), 0.25 152.1 ± 35.1 151.9 ± 35.8 -0.2 (29.5 to -29.9), -
0.004 
0.001 
Plasma CRP, mg/L 4.7 ± 4.4 1.9 ± 1.9*† -2.8 (0.03 to -5.6), -
0.78 
3.6 ± 3.9 3.0 ± 2.5 -0.6 (2.1 to -3.3), -0.20 0.045 
Fat oxidation, 
KJ/min 
1.3 ± 1.1 1.1 ± 0.9 -0.2 (0.6 to -1.0), -0.22 1.3 ± 0.8 1.3 ± 0.9 0.0 (0.7 to -0.7), 0.02 0.662 
Carbohydrate 
oxidation, KJ/min 
3.6 ± 1.9 3.1 ± 1.4 -0.5 (0.9 to -1.9), -0.30 2.7 ± 1.5 3.0 ± 2.1 0.3 (1.8 to -1.2), 0.16 0.307 
REE, kJ/min 2.5 ± 0.9 2.3 ± 1.0 -0.2 (0.6 to -1.0), -0.28 2.1 ± 0.9 2.3 ± 1.3 0.2 (1.1 to -0.7), 0.17 0.218 
Body fat, % 35.3 ± 16.4 36.6 ± 18.1 1.3 (15.7 to -13.1), 0.08 33.3 ± 9.1 33.1 ± 9.5 -0.2 (7.6 to -8.0), -0.02 
 
0.644 
Sum of skinfolds, 
mm 
36.9 ± 24.8 40.1 ± 25.4 3.2 (24.2 to -17.8), 0.13 21.5 ± 10.1 23.9 ± 14.0 2.4 (12.6 to -7.8), 0.19 0.174 
Muscle soreness 3.7 ± 0.6 4.5 ± 0.5*† 0.8 (1.3 to 0.3), -1.84 3.9 ± 0.8 3.8 ± 0.8 -0.1 (0.6 to -0.8), -0.46 0.010 
Stress levels 3.7 ± 1.0 4.6 ± 0.5*† 0.9 (1.6 to 0.2), 1.01 
 
4.0 ± 0.7 3.8 ± 0.8 -0.2 (0.4 to -0.8), 0.57 0.011 
Mood 4.0 ± 0.8 4.7 ± 0.5*† 0.7 (1.3 to 0.1), 0.94 4.1 ± 0.6 4.2 ± 0.7 0.1 (0.6 to -0.4), 0.71 0.048 
Fatigue 3.3 ± 0.7 4.3 ± 0.7 1.0 (1.6 to 0.4), 1.24 
 
3.5 ± 0.7 3.3 ± 0.7 -0.2 (0.4 to -0.8), 1.22 0.190 
Sleep quality 4.0 ± 0.7 4.0 ± 0.7 0.0 (0.6 to -0.6), 0.20 4.0 ± 0.8 4.0 ± 0.8 0.0 (0.7 to -0.7), 1.22 0.614 
General wellbeing 18.6 ± 2.9 22.1 ± 1.6*† 3.5 (5.5 to 1.5), -1.13 19.5 ± 3.0 19.8 ± 2.7 0.3 (2.7 to -2.1), 0.11 0.035 
        
 
Values are mean ± standard deviation. 1CRP, C-reactive protein; REE, Resting Energy Expenditure. 
*Different from 0 weeks to 10 weeks, P < 0.05; †Different from Control at that time, P < 0.05   
 
 
